



September 2, 2024

To whom it may concern,

Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO
(Code: 7575 TSE Prime Market)
Contact person: Takeyoshi Egawa, Vice President,
Senior Manager of Business Administration Department
(TEL. +81-3-6711-5200)

Japan Lifeline Launches Wallaby Medical's Stent Retriever


Japan Lifeline Co., Ltd. ("Japan Lifeline") is pleased to announce that it has started selling a stent retriever pRESET, from September 2024 when the product has received the reimbursement coverage in Japan. The pRESET is a neurovascular product used in the treatment of acute ischemic stroke. It is procured from phenox GmbH ("phenox"), which is a part of the WallabyPhenox Group, a subsidiary of Wallaby Medical Holding, Inc. ("Wallaby Medical"). In August 2022, Japan Lifeline entered into an exclusive 10-year distribution agreement with Wallaby Medical for their group's differentiated neurovascular portfolio in Japan.

Ischemic stroke is a serious condition caused by the blockage of blood vessels in the brain due to a blood clot. There are two main treatments for acute ischemic stroke: medication to dissolve the clot and medical devices such as catheters to access the affected area and retrieve the clot. The use of medical devices for treatment has been increasing due to the expanded indication in the revised treatment guidelines of 2019.

A stent retriever is a medical device used to treat ischemic stroke by capturing and retrieving the clot with a stent, thereby clearing the blockage in the blood vessel. The pRESET features a unique design with helical cuts in the stent and a ring-shaped stent junction. This design ensures that once the clot is captured, it is less likely to be lost during retrieval.

Following the launch of the aspiration catheter Esperance in 2023, with the introduction of the pRESET, Japan Lifeline says it will cover the major medical devices used in stroke treatment. The company expects the market size of the stent retriever to be approximately six billion yen, and it aims to capture 10 to 15 percent of market share during the medium-term management plan period (from the fiscal year ended March 31, 2024 to the fiscal year ending March 31, 2028).

Japan Lifeline will be further focusing on expanding its product lineup to solidify its presence in the neurovascular space.



Stent Retriever pRESET
Reimbursement: ¥386,000